Get More Information on Interventional oncology Market - Request Sample Report
The Interventional oncology Market Size was valued at USD 3.145 billion in 2023 and is expected to reach USD 6.862 billion by 2032 and grow at a CAGR of 9.07% over the forecast period 2024-2032.
The interventional oncology market is set to experience a significant increase since people are diagnosed with cancer more frequently, and the list of healthcare issues continues to grow internationally. Today, cancer is still a leading cause of death; therefore, there is an overwhelming tendency to use less-invasive techniques that provide precise diagnosis, high-quality treatment, and relief. According to the CDC in the United States, there were 1,603,844 new cancer cases and 602,347 cancer-related deaths in 2020. More so, up to 2021, there were approximately 1,777,566 new cases of cancer, and the rate is 439 new cases out of 100,000 people. This data proves that there is a strong tendency to cancer and the relevance of finding new interventional oncology methods. As such, the number of cases is growing, and companies are supporting a range of R&D approaches to develop a new type of treatment. Additionally, the COVID-19 situation led to certain problems. Due to lockdowns and restrictions, people were not able to visit hospitals as often as before. More so, healthcare facilities had to refuse the majority of patients since oncology was not a priority. Moreover, gatherings of people were restricted, and people were reluctant to visit medical centers. All these factors caused a high rate of missed appointments and reduced the demand for interventional oncology. However, restrictions were relieved in 2021, and the tendency to visit hospitals for cancer treatment compensated for the missed appointments. Starting from this period up to 2024, it is projected that the growth of the market will be stable, and from 2024 to 2032, the market will grow consistently. In addition, various research projects and the fact that the use of interventional oncology is the only solution for the efficient treatment of cancer support the idea that the market will grow without obstacles. For example, the NCI is taking big steps to promote research, initiate certain programs, and support funds that lead to the improvement of cancer treatment results due to new interventional oncology methods.
The fact that there are more and more cases of cancer all over the world as a result of the increase of such issues as tobacco use, poor diets, and drinking alcohol to name a few, becomes a substantial obstacle for healthcare systems. It proves that there is a growing need for more sophisticated treatment alternatives, which drive the expansion of the interventional oncology sector. The latter implies that a minimally invasive form of treating cancer issues that has gained much more practical popularity than conducting such options as surgery, radiation, and chemotherapy with the help of various benign features like the decreased extent of patients’ traumas, their shorter recovery period, and a substantially lower rate of complications. Therefore, methods like radiofrequency ablation, transarterial chemoembolization, and cryoablation prove to become more significant in cancer treatment, as they provide the most tremendous level of benefits when compared to the traditional approaches. Taking into consideration the existing and constantly increasing cancer burden, there will be a clear increase in a demand for the mentioned employme help improve the condition of the patients, affecting not only the quality of their lives but also the timeframe. For instance, in April 2021, Terumo has done its best to make a contribution to the trend, as it introduced its new global therapeutic interventional oncology team to provide better solutions for the patients and improve the quality of their lives. It is also possible to admit that a considerable market growth happens because of the increased funding of its Research and Development operations. For instance, in June 2023, Royal Philips was provided with a USD 25.97 million-deal from the IMAGIO consortium and led by Philips to care for the minimally invasive treatment of liver, lung, and soft tissue cancers. Furthermore, the Bill and Melinda Gates Foundation provided Royal Philips with an additional USD 44.6 million for the worldwide launch of its AI-powered Lumify Ultrasound System. All the funding and contributions prove that the market is expected to rise, making a certainty of the advances and innovation in the specified field.
Drivers
Increasing rates of cancer diagnoses and the rising need for more advanced Interventional Oncology treatments.
The increasing global occurrence of cancer, resulting in close to 10 million fatalities in 2020, highlights a major factor driving the interventional oncology industry. The urgent need for effective treatment methods is emphasized by the high prevalence of breast (2.26 million new cases), lung (2.21 million new cases), and colorectal cancers (1.93 million new cases) (WHO). Preventable risk factors like smoking, poor diet, and environmental toxins contribute significantly to cancer deaths, highlighting the necessity for more advanced treatment options, according to the World Health Organization (WHO). Interventional oncology, including techniques such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and cry ablation, provides important advantages compared to conventional cancer therapies. Interventional oncology is becoming more important in the battle against cancer due to its advantages such as decreased trauma, quicker recovery periods, and decreased complication rates, as mentioned by the National Cancer Institute. Technological advancements, which enhance the precision of procedures and improve patient outcomes, continue to drive the market's growth. An example of this is the $25.97 million grant given to Royal Philips for research on minimally invasive cancer treatments, which shows how substantial investments in research and development fuel innovation and acceptance in the industry. With the increasing occurrence of cancer worldwide, there is a projected increase in the need for interventional oncology options to provide efficient, less invasive treatments and enhance patient care and survival rates.
Oncology care for cancer patients is changing with the rise of Minimally Invasive Oncology.
There is a major shift happening in cancer treatment towards minimally invasive procedures, changing the treatment landscape. The transition is motivated by the many benefits these techniques provide compared to conventional surgical approaches. Minimally invasive procedures, using advanced technologies such as laparoscopy and endoscopy, offer patients numerous advantages, such as decreased surgical complications, shorter hospital stays, and reduced pain. The reduced infection risks and decreased need for post-operative care due to the smaller incisions result in faster recovery times. These benefits are especially important when it comes to treating cancer, with a focus on accuracy and ensuring the well-being of the patient.
Restraints
Difficulties in Progressing Loco regional Therapies in Interventional Immuno-Oncology
Interventional immuno-oncology is an emerging sector with great potential to transform loco regional cancer treatment. Researchers are creating new methods to specifically target and eliminate cancer cells more precisely by merging conventional interventional methods with immunotherapy. Although initial findings are positive, there are still various obstacles that need to be overcome in order to harness the full potential of this hopeful area. The complexity and cost of developing and implementing advanced interventional immuno-oncology therapies are major obstacles. Incorporating immunotherapy with conventional methods necessitates advanced technologies and skills, resulting in increased expenses and resource needs. This can restrict access and growth, especially in areas with inadequate healthcare systems. Moreover, another obstacle is presented by the requirement for healthcare professionals to undergo specialized training in order to properly administer these new treatments. In order to maximize patient outcomes and expand the scope of interventional immuno-oncology, it is essential to tackle financial and educational obstacles to ensure widespread access and successful utilization of advanced techniques.
Cost and Expertise Barriers in Interventional Oncology
The significant obstacle to market expansion is the expensive interventional oncology treatments, which are driven by the need for advanced technology and specialized equipment. Hospitals and medical centers may struggle to rationalize the significant funding required for equipment such as radiofrequency ablation, microwave ablation, and image-guided therapies. This could restrict access to these therapies in specific areas. The shortage of trained experts in conducting minimally invasive oncology treatments, especially in developing nations, is also a restricting element. The developing nations may not have enough resources to offer proper training for these healthcare workers, who require in-depth education and expertise to properly deliver these intricate treatments. The lack of trained professionals can cause patient care delays and hinder the use of interventional oncology devices.
These obstacles, related to both expense and knowledge, are anticipated to impede the expansion of the interventional oncology market in the foreseeable future. It is crucial to address these obstacles by investing more in training programs and making technologies more affordable to ensure everyone has access to these life-saving treatments.
Segment Analysis
By Type
Based on Type, Ablation Devices is capturing the largest share in Interconventional Oncology Market with 47% of the share in 2023. This section is also divided into microwave ablation, radiofrequency ablation, cryoablation, and other methods, each with unique benefits. Ablation treatments are growing in popularity because they are minimally invasive and can effectively target tumors without causing harm to surrounding healthy tissues. These treatments provide notable advantages over conventional cancer treatments like surgery and radiation, such as quicker recovery, decreased pain, and fewer complications. Key players in this field leading the way in innovation include Boston Scientific, with its advanced radiofrequency and microwave ablation technologies, and Medtronic, renowned for its advanced cryoablation devices. With the increasing number of cancer cases worldwide, there is a growing need for treatment options that are both efficient and less intrusive.
Need any customization research on Interventional oncology Market - Enquiry Now
By Cancer Type
Based on Cancer Type, Liver Cancer is capturing the largest share in Interconventional Oncology market with 34% of share of 2023. The liver cancer sector dominated the interventional oncology market in 2023 and is expected to grow at a substantial CAGR in the upcoming years. The increasing use of embolization devices, along with the rising inclination towards minimally invasive procedures in healthcare settings, is expected to drive the growth of the segment in the forecast period. Moreover, the increasing emphasis of industry participants on creating advanced liver cancer treatments with interventional devices is driving the sector.
North America dominate the Interventional Oncology Market with 36% of share in 2023. The North American interventional oncology market is poised for significant growth, driven by factors such as the increasing adoption of embolization devices, the growing preference for minimally invasive treatments, and the rising prevalence of cancer. The region's strong presence of key market players, coupled with high healthcare expenditure, favorable regulatory frameworks, and increasing awareness about minimally invasive procedures, are expected to further fuel market expansion. For instance, the American Cancer Society reported that over 800,000 people worldwide are diagnosed with liver cancer annually, highlighting the urgent need for advanced treatment solutions. In the United States, the Society of Interventional Radiology Foundation has allocated 1.5 million USD to support research in embolization and interventional oncology, underscoring the commitment to developing innovative therapies. Additionally, the high prevalence of cancer in Canada, with 239,100 expected cases in 2023, is driving demand for advanced solutions like interventional oncology. These factors collectively contribute to the lucrative growth prospects of the North American interventional oncology market.
Europe is the second fastest growing region in interventional Oncology market with 24% of share in 2023. due to several factors, including the rising prevalence of lung cancer, increased demand for cancer hospitals, improvements in healthcare infrastructure, and the growing adoption of minimally invasive cancer treatments. The European Commission's report from September 2023 indicates that cancer diagnoses in the EU rose by 2.3% to 2.7 million cases in 2022, while cancer deaths increased by 2.4% to 1.3 million. This growing burden of cancer is driving demand for advanced treatment options, such as interventional oncology, which offers minimally invasive and targeted therapies. As the region continues to invest in healthcare infrastructure and expand the availability of cancer hospitals, the demand for devices used in these procedures is expected to rise further, contributing to the overall growth of the European interventional oncology market.
Some of the Major Players are Medtronic plc, Boston Scientific Corporation, Johnson & Johnson (Ethicon), Baxter International Inc., Cook Medical, C.R. Bard Inc. (Acquired by BD), AngioDynamics Inc., Stryker Corporation, B. Braun Melsungen AG, Terumo Corporation, Siemens Healthineers, GE Healthcare and others.
In January 2024, Delcath Systems, Inc. unveiled the initial commercial application of HEPZATO KIT for treating metastatic uveal melanoma (mUM). HEPZATO KIT is a product that combines drug and device to deliver HEPZATO (melphalan) to the liver, providing increased drug levels in specific tissues and reducing overall toxicity.
In May 2023, IceCure Medical installed the ProSense System at Kovai Medical Center and Hospital in Coimbatore, India. The ProSense System is a less intrusive cryoablation technology that eliminates tumors by freezing instead of having surgery to remove them.
In September 2022, Fluidx Medical finished enrolling participants in a study for its GPX embolic tool. In the multicenter trial, GPX was utilized to target various renal adenoma tumors, both primary and metastatic, as well as arterial and venous conditions.
In March 2022, Merit Medical Systems obtained FDA authorization for Embosphere Microspheres for Genicular Artery Embolization (GAE).
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 3.145 Billion |
| Market Size by 2032 | USD 6.862 Billion |
| CAGR | CAGR of 9.07 % From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Radiation Therapy Devices, Ablation Devices {Microwave ablation, Radiofrequency ablation, Cryoablation, Others}, Embolization Device {Micro catheters, Guide wires}) • By Cancer Type(Lung Cancer, Liver Cancer, Kidney Cancer, Others) • By End-User (Hospitals, Specialty Clinics, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Medtronic plc, Boston Scientific Corporation, Johnson & Johnson (Ethicon), Baxter International Inc., Cook Medical, C.R. Bard Inc. (Acquired by BD), AngioDynamics Inc., Stryker Corporation, B. Braun Melsungen AG, Terumo Corporation, Siemens Healthineers, GE Healthcare and others |
| Key Drivers | • Advanced Interventional Oncology treatments. • Oncology care for cancer patients is changing with the rise of Minimally Invasive Oncology. |
| RESTRAINTS | • Difficulties in Progressing Loco regional Therapies in Interventional Immuno-Oncology • Cost and Expertise Barriers in Interventional Oncology |
Ans: The Interventional Oncology Market is expected to grow at a CAGR of 9.07 % during 2024-2032.
Ans: The Interventional oncology Market Size was valued at USD 3.145 billion in 2023 and is expected to reach USD 6.862 billion by 2032 and grow at a CAGR of 9.07% over the forecast period 2024-2032.
Ans: The rising prevalence of cancer is a major growth factor for the interventional oncology market.
Ans: The Ablation Devices segment dominated the Interventional Oncology Market.
Ans: North America dominated the Interventional Oncology Market in 2023.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Drug Volume: Production and usage volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Land scape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Interventional Oncology Market Segmentation, by Type
7.1 Chapter Overview
7.2 Radiation Therapy Devices
7.2.1 Radiation Therapy Devices Market Trends Analysis (2020-2032)
7.2.2 Radiation Therapy Devices Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Ablation Devices
7.3.1 Ablation Devices Market Trends Analysis (2020-2032)
7.3.2 Ablation Devices Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.1 Microwave ablation
7.3.1.1 Microwave ablation Market Trends Analysis (2020-2032)
7.3.1.2 Microwave ablation Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.2 Radiofrequency ablation
7.3.1.1 Radiofrequency ablation Market Trends Analysis (2020-2032)
7.3.1.2 Radiofrequency ablation Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3 Cryoablation
7.3.3.1 Cryoablation Market Trends Analysis (2020-2032)
7.3.3.2 Cryoablation Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4 Others
7.3.4.1 Others Market Trends Analysis (2020-2032)
7.3.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Embolization Devices
7.4.1 Embolization Devices Market Trends Analysis (2020-2032)
7.4.2 Embolization Devices Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4.1 Micro catheters
7.4.1.1 Micro catheters Market Trends Analysis (2020-2032)
7.5.1.2 Micro catheters Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4.2 Guide wires
7.4.2.1 Guide wires Market Trends Analysis (2020-2032)
7.4.2.2 Guide wires Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Interventional Oncology Market Segmentation, By Cancer Type
8.1 Chapter Overview
8.2 Lung Cancer
8.2.1 Lung Cancer Market Trends Analysis (2020-2032)
8.2.2 Lung Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Liver Cancer
8.3.1 Liver Cancer Market Trends Analysis (2020-2032)
8.3.2 Liver Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Kidney Cancer
8.4.1 Kidney Cancer Market Trends Analysis (2020-2032)
8.4.2 Kidney Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Others
8.4.1 Others Market Trends Analysis (2020-2032)
8.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Interventional Oncology Market Segmentation, by End User
9.1 Chapter Overview
9.2 Hospitals
9.2.1 Hospitals Market Trends Analysis (2020-2032)
9.2.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Specialty Clinics
9.3.1 Specialty Clinics Market Trends Analysis (2020-2032)
9.3.2 Specialty Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Others
9.4.1 Others Market Trends Analysis (2020-2032)
9.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Interventional Oncology Market Estimates and Forecasts, By Country (2020-2032) (USD Billion)
10.2.3 North America Interventional Oncology Market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
10.2.4 North America Interventional Oncology Market Estimates and Forecasts, By Cancer Type(2020-2032) (USD Billion)
10.2.5 North America Interventional Oncology Market Estimates and Forecasts, By End User (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Interventional Oncology market Estimates and Forecasts, By Type (2020-2032) (USD Billion)
10.2.6.2 USA Interventional Oncology market Estimates and Forecasts, By Cancer Type(2020-2032) (USD Billion)
10.2.6.3 USA Interventional Oncology market Estimates and Forecasts, By End User (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.7.2 Canada Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.2.7.3 Canada Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.2.8.2 Mexico Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.2.8.3 Mexico Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Interventional Oncology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Interventional Oncology market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.6.2 Poland Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.3.1.6.3 Poland Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.7.2 Romania Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.3.1.7.3 Romania Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.3.1.8.3 Hungary Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.3.1.9.3 Turkey Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Interventional Oncology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.4 Western Europe Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.3.2.5 Western Europe Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.6.2 Germany Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.3.2.6.3 Germany Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.7.2 France Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.3.2.7.3 France Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.8.2 UK Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.3.2.8.3 UK Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.9.2 Italy Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.3.2.9.3 Italy Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.10.2 Spain Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.3.2.10.3 Spain Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.13.2 Austria Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.3.2.13.3 Austria Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Interventional Oncology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.4 Asia Pacific Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.4.5 Asia Pacific Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.6.2 China Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.4.6.3 China Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.7.2 India Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.4.7.3 India Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.8.2 Japan Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.4.8.3 Japan Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.9.2 South Korea Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.4.9.3 South Korea Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.10.2 Vietnam Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.4.10.3 Vietnam Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.11.2 Singapore Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.4.11.3 Singapore Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.12.2 Australia Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.4.12.3 Australia Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Interventional Oncology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.4 Middle East Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.5.1.5 Middle East Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.6.2 UAE Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.5.1.6.3 UAE Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.5.1.7.3 Egypt Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Smartphone Sensors Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Smartphone Sensors Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.5.1.9.3 Qatar Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Interventional Oncology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.4 Africa Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.5.2.5 Africa Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.5.2.6.3 South Africa Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Interventional Oncology Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.4 Latin America Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.6.5 Latin America Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.6.2 Brazil Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.6.6.3 Brazil Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.7.2 Argentina Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.6.7.3 Argentina Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.8.2 Colombia Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.6.8.3 Colombia Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Interventional Oncology Market Estimates and Forecasts, by Type (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Interventional Oncology Market Estimates and Forecasts, by Cancer Type(2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Interventional Oncology Market Estimates and Forecasts, by End User (2020-2032) (USD Billion)
11. Company Profiles
11.1 Medtronic plc
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 Boston Scientific Corporation
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Johnson & Johnson (Ethicon)
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Baxter International Inc.
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Cook Medical
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 C.R. Bard Inc. (Acquired by BD)
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 AngioDynamics Inc.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Stryker Corporation
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 B. Braun Melsungen AG
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Terumo Corporation
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Type
Radiation Therapy Devices
Ablation Devices
Microwave ablation
Radiofrequency ablation
Cryoablation
Others
Embolization Devices
Micro catheters
Guide wires
By Cancer Type
Lung Cancer
Liver Cancer
Kidney Cancer
Others
By End-User
Hospitals
Specialty Clinics
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Virtual Fitness Market size was estimated at USD 16.03 billion in 2023 and is expected to reach USD 151.35 billion by 2032 at a CAGR of 28.35% during the forecast period of 2024-2032.
The Weight Loss Devices Market Size was valued at USD 5.30 Billion in 2023 and is expected to reach USD 8.50 Billion by 2032 and grow at a CAGR of 6.60% over the forecast period 2024-2032.
The Newborn Screening Market was valued at USD 880 Million in 2023 and is expected to reach USD 1710.7 million by 2032, growing at a CAGR of 7.68% over the forecast period 2024-2032.
Liver Disease Diagnostics Market was valued at USD 35.97 billion in 2023 and is expected to reach USD 64.23 billion by 2032, growing at a CAGR of 6.69% from 2024-2032.
The global eHealth Market size was valued at USD 346.94 billion in 2023 is projected grow at a CAGR of 18.26% to reach USD 1567.73 billion by 2032.
The Epilepsy Surgery Market Size was valued at USD 1.20 billion in 2023 and is expected to reach USD 2.00 billion by 2032 and grow at a CAGR of 5.87% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
